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Abstract: Cardiovascular disease (CVD) is responsible for ~27% of deaths worldwide, with 80% of these occuring in developing 
countries. Hypertension is one of the most important treatable factors in the prevention of CVD. Angiotensin-I converting enzyme (ACE) 
is a two-domain dipeptidylcarboxypeptidase that is a key regulator of blood pressure as a result of its critical role in the renin-
angiotensin-aldosterone and kallikrien-kinin systems. Consequently, ACE is an important drug target in the treatment of CVD. ACE is 
primarily known for its ability to cleave angiotensin-I to the vasoactive octapeptide angiotensin-II, but is also able to cleave a number of 
other substrates including the vasodilator bradykinin and N-acetyl-seryl-aspartyl-lysyl-proline (acetyl-SDKP), a physiological modulator 
of hematopoiesis. Numerous ACE inhibiors are available clinically, and these are generally effective in treating hypertension. However 
some adverse effects are associated with ACE inhibition, such as the persistent dry cough and the potentially fatal angioedema. The 
solution of ACE crystal structures over the last decade has facilitated rational drug design which has contributed to the development of 
domain-selective ACE inhibitors, the most notable of which include RXP407 (N-domain) and RXPA380 (C-domain), which in principle
may herald new therapeutic approaches for ACE inhibition. Additionally, dual inhibitors to ACE and other targets such as neprilysin, 
endothelin converting enzyme and chymase have been developed. The success of ACE inhibitors has also led to the search for novel
inhibitors in food and natural products and the structure guided screening of such libraries may well reveal a number of new ACE
inhibitors. 
Keywords: Angiotensin-I converting enzyme, cardiovascular disease, crystal structure, domain selective inhibitors, hypertension, structure-
based drug design, zinc metallopeptidase. 
1. INTRODUCTION 
Cardiovascular disease (CVD) due to hypertension, 
atherosclerosis and diabetes is the leading cause of death, 
accounting for 30% of deaths worldwide, with 80% of these deaths 
occurring in middle and low income countries [1,2]. The principal 
source of morbidity and mortality from CVD is due to end-organ 
damage, notably heart failure, nephropathy and retinopathy, due in 
large part to organ fibrosis. 
Current treatment regimens for CVD and the underlying 
predisposing conditions are inadequate, and poorly controlled 
hypertension, atherosclerosis and diabetes are the norm rather than 
the exception. Consequently, progression of established heart 
failure, nephropathy and retinopathy can at best be slowed but not 
halted.  
The importance of angiotensin-I converting enzyme (EC 
3.4.15.1, ACE) and its critical role in the renin-angiotensin 
aldosterone system (RAAS) in relation to cardiovascular 
physiology and disease has been firmly established. This is mainly 
due to the fact that the drugs that block various components of this 
system are effective as treatments for hypertension, heart failure 
and prevention of vascular events caused by atherosclerosis (mainly 
heart attack and stroke), as well as slowing kidney disease caused 
by hypertension or diabetes. ACE inhibitors have been used 
clinically (Table 1), but there is still room for improvement given 
the side effects seen in patients on long-term treatment.  
1.1. Angiotensin-I Converting Enzyme (ACE) 
ACE is a zinc metallopeptidase that plays a critical role in 
blood pressure regulation by catalyzing the proteolysis of 
angiotensin-I to the vasopressor angiotensin-II [3-8]. Human ACE 
is a type I transmembrane protein of 1,306 amino acids and is 
processed to a 1277-residue mature form which is heavily 
glycosylated (Fig. 1). A sequence of 22 hydrophobic amino acids 
located near the carboxy terminus of the protein serves as a  
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transmembrane domain that anchors ACE to the cell surface. Thus, 
ACE contains a 28-residue cytosolic domain and a 1249-residue 
glycosylated extracellular domain. ACE is also a member of a large 
family of proteins that undergo cleavage, with release of their 
ectodomain as a soluble form of the protein [9].  
There are two isoforms of human ACE: in somatic tissues, it 
exists as a glycoprotein composed of a mature single polypeptide 
chain of 1277-amino acids (sACE), with an active centre on both 
the N- and C-domains [10] (Fig. 1). In male germinal cells, it is 
synthesised as a lower molecular mass form and is thought to play a 
role in sperm maturation and the binding of sperm to the oviduct 
epithelium [11]. However the full nature of its role is still under 
investigation [12-14]. This isoform, testis ACE (tACE) is identical 
to the C-terminal half of somatic ACE, except for a unique 36-
residue sequence constituting its amino terminus [15].  
Despite sharing ~55% sequence identity with the C-domain, the 
N-domain of sACE has its own distinctive physicochemical and 
functional properties. It is thermally more stable than the C-domain 
[16], more resistant to proteolysis under denaturing conditions [17] 
and is less dependent on chloride activation as compared with the 
C-domain [18,19]. Both domains are heavily glycosylated (the N-
domain has ten and the C-domain has seven N-linked glycosylation 
sites), a feature that has hampered the three-dimensional structure 
determination of the protein for a long time. The different glycan 
profile of the N-domain is likely to be responsible for the 
carbohydrate-mediated dimerisation of the somatic form which has 
been described under certain conditions [20]. Substrates such as the 
hemoregulatory and antifibrotic peptide N-acetyl-seryl-aspartyl-
lysyl-proline (AcSDKP) [21], and the enkephalin precursor [22] 
Met5-Enk-Arg6-Phe7 are specific for the N-domain, whereas the 
physiological substrates bradykinin and angiotensin-I are 
hydrolysed with similar catalytic efficiency as the C-domain, in 
vitro. Interestingly, the N-domain preferentially hydrolyses the 
amyloid beta peptide of the amyloid precursor protein resulting in 
inhibition of amyloid beta aggregation and cytotoxicity in cell-
based assays [23]; although this is not necessarily the case in vivo 
[24]. The N-domain may also have a role in modulating C-domain 
activity through a combination of inter-domain cooperativity and 
structural stabilisation. 
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Table 1. N- and C- Domain Selectivity of Known (Current) ACE Inhibitors 
Inhibitor residues* Domain inhibition (nM)‡
Inhibitor  -P2  -P1  -P1   -P2 N-domain C-domain 
BPPa –Gln–Ile–Pro–Pro 100.0 1.0 
BPP-10c –Gln–Ile–Pro–Pro 200.0 0.5 
BPPb –Lys–Ile–Pro–Pro 10000.0 30.0 
BPPc –Pro–Ile–Pro–Pro 80.0 80.0 
bBPP-12b –Pro–Ile–Pro–Pro 5.0 150.0 
Ang1-7 –Tyr–Ile–His–Pro 3400.0 130.0 
RXPA380 Phe–Phe–Pro–Trp 10000.0 3.0 
RXP407 Ac-Asp–Phe–Ala–Ala–NH2 2.0 2500.0 
Captopril  Ala–Pro 8.9 14.0 
Enalapril Phe–Ala–Pro 26.0 6.3 
Lisinopril Phe–Lys–Pro 44.0 2.4 
Keto-ACE  Bnz–Phe–Gly–Pro 1500.0 40.0 
Trandolapril Phe–Ala–Trp 3.1 0.3 
*C-terminal amino-acid residues of peptide inhibitors (BPP peptides and Ang1-7), or amino-acid analogs in the phosphinic peptides (RXPA380 and RXP407) and small-molecule 
ACE inhibitors (captopril, enalapril, lisinopril, keto-ACE, and trandolapril). ‡Determined as Ki in every case except keto-ACE (IC50), at 150 mM NaCl (keto-ACE and Ang1-7 [22]), 
200 mM NaCl (BPP and phosphinic peptides [69,96]), or 300 mM NaCl (small-molecule inhibitors [18]). 
Fig. (1). Domain structure of somatic (sACE) and testis ACE (tACE or C-domain of ACE) indicating the catalytic domains, the inter-domain linker region 
(LR), the transmembrane domain (TM), and cytoplasmic domain (CT).
In 1977 Cushman et al. described the synthesis of a series of 
potent inhibitors of ACE designed on the basis of an assumed 
mechanistic homology with carboxypeptidase A [25]. This ushered 
in a generation of drugs for the management of hypertension, many 
of which are still used today. Remarkably, these inhibitors were 
developed without the benefit of any detailed chemical, kinetic or 
structural information on human ACE. Despite intensive efforts by 
several research groups since the 1970’s, the ACE crystal structure 
could not be determined until 2003. This has largely been due to the 
inability to generate ACE proteins, from natural or recombinant 
sources, that could yield crystals suitable for structural study. These 
problems were eventually circumvented resulting in the solution of 
the first ACE structure [26]. This research showed that the structure 
of ACE (Fig. 2) is different from carboxypeptidase (used as a 
model for the design of well known and marketed ACE inhibitor 
captopril [25]) but similar to neurolysin, an unexpected similarity 
when comparing the amino acid sequences. The structure of tACE 
bound to the potent inhibitor lisinopril [18,27,28] showed that the 
inhibitor binds in a highly ordered, extended conformation [26] 
(Figs. 2A, B). The interactions of the inhibitor were found to be 
different from those for captopril, although they did encompass 
some features of what was envisaged in the early work. Thus, the 
research by Natesh et al. [26] not only represents an important 
scientific achievement in defining the structure of ACE for the first 
time, but also provided new and enlightening information.  
Captopril differs from both lisinopril and enalaprilat in that its 
sulphydryl group coordinates the zinc rather than a carboxyl group. 
Its smaller size also results in less direct interactions with the 
protein, being held in place at only two positions, in addition to the 
zinc coordinating group. It was also found that the trend in the 
relative potencies of lisinopril, enalaprilat and captopril for the C-
domain (L > E > C) [18], correlates with the number of interactions 
observed in the crystal structure complexes with tACE [29] and 
provided the details of the framework of residues important for 
drug binding.  
Based on a similar strategy, batches of N-domain (sACE 
residues 1-629), expressed in Chinese hamster ovary (CHO) cells in 
the presence of alpha-glucosidase inhibitor N-butyldeoxy-
nojirimycin (NB-DNJ), were subjected to extensive crystallisation 
trials, which eventually yielded crystals that diffracted to 2.9 Å 
resolution. The structure (both in the presence and absence of 
lisinopril) gave the first clues as to how these two domains differ in 
specificity and function. These structures of the highly homologous 
N- and C-domains provided a platform for the beginning of the 
design of next generation ‘domain-specific’ ACE inhibitors [30] 
(Fig. 2C).
2. CURRENT ACE INHIBITORS: ADVANTAGES AND 
LIMITATIONS 
ACE inhibition is an approach for the treatment of hypertension 
and CVD that has been championed for over 30 years. Our 
understanding of the impact of ACE inhibitors in the early 80s 
could well be described as seeing through a glass, darkly compared 
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to our current knowledge of all the angiotensin-related peptides and 
their cognate receptors; the interactions and relative contributions 
of the different blood pressure regulating cascades; and the cell 
signalling mechanisms. The fact that they have withstood rigourous 
testing in large clinical studies and are still so widely used today, 
bears testimony to their success.  
ACE inhibitors are one of the front-line therapies for essential 
hypertension. In both hypertensive and salt-depleted normotensive 
subjects they show efficacy in lowering mean systolic and diastolic 
pressures [31,32]. One of their hallmarks is that they decrease 
peripheral vascular resistance without altering baroreceptor activity 
[33] or causing an increase in heart rate [34-36], while also 
inhibiting the tonic effect of angiotensin-II on the sympathetic 
nervous system [37]. The advantages of ACE inhibitors in the 
treatment of atherosclerosis, congestive heart failure, myocardial 
infarction, diabetic nephropathy, plaque stabilization and cancer 
have been reviewed previously [38]. 
ACE hydrolyses a diverse range of substrates including 
AcSDKP, gonadotropin-releasing hormone (GnRH) [also known as 
luteinizing-hormone-releasing hormone (LHRH)], substance P, 
neurotensin, dynorphin and enkephalin and thus ACE inhibition 
results in a variety of effects independent of blood pressure 
reduction [39]. Hence, ACE inhibitors augmented the effects of 
bradykinin in blood vessels that had negligible levels of ACE and 
increased the effect of ACE-resistant B2-kinin receptor agonist [40]. 
These data support the notion that ACE inhibitors selectively 
potentiate the vascular effects of bradykinin mediated by the B2-
receptor, independently of their ACE inhibiting properties. 
Furthermore, ACE has been shown to dimerise with the B2-kinin 
receptor resulting in the protection of high-affinity receptors, 
blocking receptor desensitization, and decreasing internalisation 
thereby potentiating bradykinin beyond simply preventing its 
hydrolysis [41,42]. 
Kohlstedt et al. showed that ACE inhibitors are able to induce 
phosphorylation of Ser1270 located in the cytoplasmic domain of 
ACE resulting in outside-in signalling that increases expression of 
cyclooxygenase-2 and ACE [43]. The ACE inhibitor effect on 
cyclooxygenase-2 is caused by the transcription factor activator 
Fig. (2). Structure of tACE [26]. A). Cartoon representation with zinc ion (large sphere), chloride ions in small spheres, and the ACE inhibitor lisinopril 
(black) bound in the active site. B). Surface representation of tACE active site cavity with bound lisinopril (black). C). Comparison with the N domain (thin 
line), the zinc ion is shown in large sphere [30]. 
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protein and this results in an increased release of prostacyclin and 
prostaglandin E2 by endothelial cells [44]. 
The most common adverse effect of ACE inhibitors is a 
persistent cough which can affect as many as one in five subjects in 
certain populations. Angioedema, on the other hand, is a much rarer 
side effect, but potentially life-threatening. It is widely accepted 
that these effects are caused by elevated levels of bradykinin or 
substance P and stimulation of vagal C fibers [45]. Furthermore, 
ACE inhibitors lead to lower levels of aldosterone which can cause 
hyperkalemia, especially in patients with poor kidney function or 
patients on potassium supplements [46-48]. 
Sulfhydral-containing ACE inhibitors have been associated 
with skin rash, neutropenia and nephrotic syndrome and these side 
effect are often associated with concomitant end organ disease 
(especially renal insufficiency) [49]. Initially captopril was 
administered at doses that are now recognised to be far in excess of 
those necessary for drug action and this likely aggravated the 
adverse effects. Moreover, dosages were given without considering 
deficiencies of renal function, now known to be the main excretory 
route of captopril. In contrast to these adverse effects caused by 
other sulfhydryl ACE inhibitors, long-term treatment with 
zofenopril may slow the progression of carotid atherosclerosis in 
addition to its blood pressure lowering effect [50]. 
Chronic use of ACE inhibitors can lead to ACE inhibitor 
escape, where levels of angiotensin-II are not reduced to normal 
despite substantial ACE inhibition. One of the mechanisms for 
ACE inhibitor escape is the hydrolysis of angiotensin-I by the 
serine protease chymase, found in cardiac interstitial space and 
cardiac endothelial cells [51]. Recently, Wei et al. showed that 
chronic ACE inhibition resulted in a marked increase in left 
ventricle chymase activity mediated by bradykinin/B2 receptor in 
mice [52]. Moreover, combination of ACE and chymase inhibition 
improved left ventricle function, decreased adverse cardiac 
remodelling and improved survival post myocardial infarction. 
Thus, some of the ‘limitations’ of ACE inhibitors involving 
ACE’s substrate promiscuity and other enzymes ability to 
hydrolyse its primary physiological substrate have heralded 
possibilities for fine tuning the RAAS using combination therapies 
and dual peptidase (vasopeptidase) inhibitors. It is likely that these 
advances in our understanding of ACE and its blockade will result 
in further additions to the arsenal of drugs for the treatment of 
hypertension and CVD and hopefully a more precise approach 
towards personalised medicine. 
3. MINIMUM GLYCOSYLATION REQUIREMENTS FOR 
THE EXPRESSION AND CRYSTALLISATION OF ACE  
The use of protein crystal structures solved in complex with 
specific inhibitors is a valuable tool for rational drug design. Given 
the importance of ACE inhibitors in the treatment of cardiovascular 
disease, numerous efforts have been made to solve the X-ray crystal 
structure of this protein. Attempts to crystallise the full length 
sACE enzyme have as yet been unsuccessful. This is most likely 
due to a high level of surface glycosylation and the flexibility of the 
linker region, joining the two domains. However, the complex 
problem of sACE crystallisation has been solved in part by 
attempting to crystallise the N- and C-domains separately.  
While researchers have been able to crystallise the individual 
N- and C-domains, this was not a trivial matter. Initial attempts to 
crystallise tACE (equivalent to the C-domain of ACE) were 
unsuccessful. Thus a truncated form was developed by the removal 
of the transmembrane region at the C-terminus, and a heavily O-
glycosylated region at the N-terminus (not present in the C-domain 
of sACE). This shortened, soluble form of the enzyme, expressed in 
the presence of a glucosidase inhibitor NB-DNJ, and treated with 
endoglycosidase-H (which leaves just a single N-acetylglucosamine 
residue attached to the Asn of the glycosylation sequon), was able 
to form diffracting crystals and led to the solution of the first X-ray 
crystal structure for human tACE [26]. The solution of the N-
domain structure was also hampered by the high degree of surface 
glycosylation and once again, expression in the presence of the 
glucosidase inhibitor, NB-DNJ, was required to produce a 
crystallisable form of the N-domain [30]. Although the use of NB-
DNJ allowed for the solution of the crystal structure for the N- and 
C-domains, in both cases crystallisation was not reproducible, and 
combined with the high cost of NB-DNJ, this approach was deemed 
unfeasible for routine use. 
Since N-glycosylation is required for the folding of ACE into its 
active conformation [53,54], attempts were made to determine the 
minimum number of N-glycosylation sites required for the 
expression of functional N- and C-domains of ACE. Producing 
forms of the N- and C-domains which contained the fewest possible 
number of intact glycosylation sites would reduce glycan 
complexity and avoid the need for expensive glycosylation 
inhibitors.  
Mass spectrometry based studies on tACE revealed that 
although glycosylation was found at six of the seven potential N-
glycosylation sites on the C-domain, only the three N-terminal sites 
were consistently found in the glycosylated state, with the three C-
terminal sites being found in both the glycosylated and 
unglycosylated forms [55]. These data seemed to imply that the N-
terminal sites were of particular importance for the C-domain. 
Therefore, extensive site-directed mutagenesis of the various 
glycosylation sites was carried out, disrupting the glycosylation 
sites from the C-terminus. Results from this study revealed that 
glycosylation of only one or two of the N-terminal sites was 
required for expression of an active glycoform of the C-domain 
[54] (Fig. 3A). Using one of these hypoglycosylated forms of 
tACE, tACEg1,3 (tACE containing glycosylation at only sites one 
and three), reproducible and diffraction-quality crystal formation 
was achieved [56]. An alignment of the two C-domain crystal 
structures, shows that they are essentially identical, with a root-
mean square deviation (RMSD) of 0.51 Å for all atoms [57], 
indicating that mutation of the glycan sequons did not affect the 
structure of the enzyme.  
Mass spectrometry studies revealed that virtually all of the ten 
N-glycosylation sites on the N-domain were glycosylated, with only 
one site found to be unglycosylated, while one site was not detected 
[58]. Therefore, no inference about the relative importance of the 
different glycosylation sites could be made. However, given the 
high degree of structural similarity between the N- and C-domains 
(RMSD of 0.72 Å for all atoms) it was expected that the generation 
of a similarly hypoglycosylated form of the N-domain would be 
suitable for high throughput inhibitor-enzyme crystallisation 
studies. Thus, glycosylation sites were sequentially disrupted from 
the N-terminus. However, in contrast to the C-domain where N-
terminal glycosylation was important, it was found that C-terminal 
glycosylation was required for the expression of functional N-
domain [58]. Further investigation revealed that three C-terminal 
glycosylation sites (sites seven, eight and nine) were sufficient for 
the expression of functional N-domain, although an N-terminal site 
was able to compensate for the absence of a C-terminal site, such 
that Ndom389 (N-domain containing glycosylation at sites three, 
eight and nine) was expressed as an active N-domain glycoform 
[58] (Fig. 3B). Recent crystallization trials with this variant have 
shown that it is able to crystallize reproducibly, the best of which 
diffracted to 2.0 Å resolution [58]. It is often a concern that 
introducing mutations may affect the structure of the protein, which 
would be problematic for this approach to crystal structure 
determination. However, aligning the structures of wild type N-
domain and Ndom389 revealed an RMSD of 0.70 Å for all atoms 
[57]. 
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4. DOMAIN SELECTIVE ACE INHIBITORS 
4.1. N-Domain Inhibitors 
The N-domain has been shown to be the main site involved in 
the cleavage of Angiotensin (1-7) [Ang1-7], amyloid beta peptide 
(A-beta42), GnRH and AcSDKP [21,22,59], although others have 
shown the hydrolysis of Ang1-7 is not domain-selective [60]. 
Perhaps the most important of these is AcSDKP. This substrate was 
first identified as a regulatory peptide involved in hematopoietic 
stem cell proliferation [61], but has also been shown to have a 
number of beneficial effects on the cardiac system. These include 
preventing or reversing cardiac, vascular and renal inflammation 
and fibrosis [62]. AcSDKP mediates these effects, in part, by 
inhibiting macrophage differentiation, activation, migration and 
cytokine release. AcSDKP has also been shown to prevent end-
organ damage resulting from hypertension [63], as well as 
protecting against diabetic cardiomyopathy [64]. Additionally, 
increased levels of AcSDKP, following ACE inhibition, are thought 
to contribute to the beneficial effects of ACE inhibitors by a novel 
mechanism whereby AcSDKP inhibits collagen deposition in the 
left ventricle of the heart following vascular injury [65]. N-domain 
knock-out mice, and mice undergoing chronic ACE inhibitor 
treatment, have AcSDKP levels six to seven times that of wild-type 
(WT) mice [66-68], illustrating the importance of the N-domain in 
the regulation of AcSDKP levels. 
Not surprisingly, these findings highlight the value of 
developing inhibitors selective for the N-domain of ACE, which 
may prove useful in the treatment of certain diseases such as renal 
and pulmonary fibrosis, where inhibition of the N-domain could be 
beneficial, while the C-domain would remain active to allow for 
normal regulation of blood pressure.  
The most notable N-domain selective inhibitor is RXP407, 
which displays roughly 2000-fold selectivity for the N-domain 
(Table 1) [69]. The S2 pocket residues Tyr369 and Arg381 have 
been implicated in conferring the N-domain selectivity of this 
inhibitor (Fig. 4D), positioning RXP407 in an optimal conformation 
for the N-domain active site [70]. These findings further confirm 
those established during the synthesis of RXP407, where it was 
found that varying the P2 group had a notable effect on the 
selectivity of the inhibitor [69]. Furthermore, Dive et al. [69] found 
that the presence of a Glu, Asn or Asp at the P2 position promoted 
N-selectivity, while the presence of an Arg at the P2 position 
reversed the N-selectivity of the inhibitor. The importance of the S2
pocket in conferring the selectivity of RXP407 was further 
highlighted in the crystal structure of the N-domain in complex 
with this inhibitor, which showed that both Tyr369 and Arg381 
make close contacts with the P2 group of RXP407 (Figs. 4C and D)
[58]. 
4.2. C-Domain Inhibitors 
Recent findings have shown that the major site of angiotensin-I 
cleavage is at the C-domain active site [68,71], while both domains 
cleave bradykinin with equal efficiency [19]. These findings have 
given rise to the pursuit of C-domain selective inhibitors which, it is 
hoped, will provide control of blood pressure, while leaving the N-
domain active to prevent bradykinin accumulation and the 
associated side effects [72].  
Keto-ACE, a ketomethylene analogue of the tripeptide Phe-
Gly-Pro, is about 50-fold more selective for the C-domain of ACE 
and was the first ACE inhibitor to display notable domain-
selectivity (Table 1) [22]. The domain-selectivity of this inhibitor 
has subsequently been improved by adding a bulky hydrophobic 
group at the P2 position [73]. For example, changing the P2 Pro to 
a Trp or Phe causes the domain selectivity to increase to about 250-
fold in favor of the C-domain. The selectivity of the keto-ACE 
derivatives is likely due to interactions between the aromatic P2
group and the S2 residues Glu367 and Val380 in the C-domain 
[74]. These interactions are lost in the N-domain were the residues 
in question are replaced by the polar residues Asp354 and Thr358, 
respectively. It has been suggested that hydrophobic interactions 
Fig. (3). Schematic representation of the glycosylation sites on the N- and C-domains of ACE showing the minimum number of glycosylation sites required 
for expression and crystallisation of the N- and C-domains. Black boxes indicate intact glycosylation sites. 
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mediated by C-domain residues Phe391 (S2) and Val518 (P1) also 
contribute to C-domain selectivity of the ketoACE derivatives, as 
these residues are replaced by more polar amino acids in the N-
domain (Tyr369 and Thr496 respectively) [74]. 
The bradykinin potentiating peptide pGlu-Gly-Leu-Pro-Pro-
Arg-Pro-Lys-Ile-Pro-Pro (BPPb) also shows about 260-fold C-
domain selectivity (Table 1) [75]. The selectivity of the BPPs’ is 
thought to be mediated by the P2 residue. Thus, the presence of the 
P2 Lys in BPPb, as opposed to the Gln, Pro and Pro in BPPa, BPP2 
and BPPc respectively, drives the C-domain selectivity of this 
peptide. 
The most potent C-domain selective inhibitor to date is the 
phosphinic peptide analogue RXPA380, which is approximately 
2000-fold more C-domain selective (Table 1) [76]. Based on the 
crystal structure of C-domain in complex with RXPA380 inhibitor 
[77] and mutagenesis studies, the potency of this inhibitor has been 
attributed largely to hydrophobic interactions between the P2 group 
and Phe391, which is replaced by the more polar Tyr369 in the N-
domain may present a steric clash with the P2 Phe of RXPA380 
binding (Figs. 4A and B) [70]. Additionally, the C-domain S2
pocket residue Glu403 is replaced by Arg381 in the N-domain, and 
may also cause steric clash with the P2 group, further contributing 
to the C-domain selectivity of this inhibitor. Interestingly, Asp354 
and Glu403, which were implicated in the selectivity of the keto-
ACE derivatives, did not appear to affect domain selectivity of 
RXPA380 [70]. 
However, the future of C-domain selective inhibitors has been 
coloured by recent murine studies which have shown that genetic 
inactivation of the C-domain did not result in a decrease in blood 
pressure, due to a compensatory mechanism involving the 
upregulation of renin [71]. This upregulation of renin allows for the 
maintenance of regular blood pressure, despite the absence of the 
C-domain activity [71,78]. Thus, it is possible that the use of C-
domain selective ACE inhibitors for the treatment of chronic 
hypertension may not be as effective as initially thought. The 
development of dual C-domain/endothelin converting enzyme 
inhibitors, however, may be one possible solution to this problem. 
5. DUAL ACE-ECE INHIBITORS 
Apart from ACE, neutral endopeptidase (neprilysin, NEP, EC 
3.4.24.11) and endothelin converting enzyme-1 (ECE-1, EC 
3.4.24.71) also exert vasoconstrictive and vasodilatory activities. 
Hence both NEP and ECE-1 have proven to be suitable targets for 
the treatment of cardiovascular disease [7,79-83]. However, 
considerable side-effects have been documented, most likely due to 
elevated levels of bradykinin [45,84]. Moreover, it is now known 
that ACE inhibition can induce an increase in chymase activity in 
cardiac interstitial fluid and hence provides a different mechanism 
for the accumulation of angiotensin-II [52]. Hence, blood pressure 
control remains sub-optimal in a significant proportion of patients 
on this therapy [85], providing a compelling case for the 
development of new improved strategies. To address this concern, 
potent vasopeptidase inhibitors able to target ACE and NEP were 
developed [86,87], followed by dual NEP/ECE-1 inhibitors and 
ultimately triple inhibitors blocking ACE/NEP/ECE-1 
simultaneously [88]. Even though the dual ACE/NEP inhibitor 
Fig. (4). Stick representation of the active site residues involved in inhibitor selectivity for the C-domain (phosphinic peptide RXPA380) [77] and N-domain 
(phosphinic peptide RXP407) [58] of ACE. A) The C-domain specific inhibitor RXPA380 is shown; B) structure-based superposition of RXPA380 molecule 
in the active site of N-domain; C) structure-based superposition of RXP407 molecule in the active site of C-domain and D) The N-domain specific inhibitor 
RXP407 is shown. 
Q259
K489
H491
T496
H331
Y498
Q281
K511H513
V518 H353
A B
S260
E431
T358
RXPA380
T282
V380
RXPA380
H361
H365
Y369R381
D453
V379
H383E411
H387
A356
F391
E403 CDomain NDomain
K511H513
K489
H491
C D
RXP407
Q281
T282
V518 H353 Q259
S260
T496
H331
Y498
RXP407
D453
V379
V380
H383E411
A356
E431
T358
H361
H387E403 H365
Y369R381CDomain NDomain
Human ACE Inhibitor Design Current Medicinal Chemistry,  2012 Vol. 19, No. 6      851
omapatrilat was more clinically efficacious than a single ACE 
inhibitor, the higher incidence of angioedema observed in patients 
treated with omapatrilat halted the development of omapatrilat and 
raised concerns about the risk/benefit ratio of dual ACE/NEP 
inhibitors for therapeutic applications [89]. While the level of 
angioedema associated with triple ACE/NEP/ECE-1 inhibitor 
treatment is yet to be evaluated, it has been suggested that NEP 
inhibition (in the context of either dual or triple inhibitor treatment) 
might be responsible for the increase in adverse effects [88]. Indeed 
it has been established that inhibition of NEP results in increased 
levels of bradykinin and endothelin-I (ET-I). These data initiated 
the development of novel inhibitors that interact with the C-domain 
of ACE and ECE-1 [90]. This led to the discovery of the first potent 
and selective dual C-domain ACE/ECE-1 inhibitors and revealed 
that the configuration of the P1 residue was a key factor in the 
control of inhibitor selectivity (Fig. 5). Instead of the classical S
configuration of the inhibitor’s P1 group (corresponding to an L-
amino acid, as observed in all ACE inhibitors known to date) 
(compound FI in Fig. 5), it was discovered that an R configuration 
in compounds (compound FII in Fig. 5) containing long and bulky 
P1 side chains was well accommodated by ACE, as well as by 
ECE-1, but much less so by NEP [90]. Furthermore, in a 
spontaneous hypertensive rat (SHR) model, an intravenous 
administration of C-domain ACE/ECE-1 dual inhibitor (FII) (10 
mg/kg) lowered the mean arterial blood pressure by 24 ± 2 mm/Hg 
as compared with controls [90]. Thus, targeting both ACE and 
ECE-1 lowers plasma concentrations of angiotensin-II and 
endothelin-I, the two most potent vasoconstrictve peptides without 
increasing the bradykinin levels.  
A structural basis for the binding of a highly potent and 
selective dual ACE/ECE-1 phosphinic inhibitor was provided by 
the first structures in complex with the C- (at 1.97 Å) and N-domain 
of ACE (at 2.15 Å) [57]. The structural determinants revealed the 
unique features of the binding of two molecules of the dual 
inhibitor in the active site of the C-domain of ACE (Figs. 6A and 
C) and one molecule in the active site of the N-domain of ACE 
(Figs. 6B and D), respectively. In both structures, the first molecule 
was positioned in the obligatory binding site and has a bulky 
bicyclic P1 residue with the unusual R configuration which, 
surprisingly, was accommodated by the large S2 pocket (Fig. 6). In 
the C-domain complex, the isoxazole phenyl group of the second 
molecule makes strong pi-pi stacking interactions with the amino 
benzoyl group of the first molecule locking them in a ‘hand-shake’
conformation. These features for the first time highlighted the 
unusual architecture and flexibility of the active site of the C-
domain of ACE, which could be further utilized for structure-based 
design of new C-domain or vasopeptidase inhibitors. 
6. LESSONS IN ACE INHIBITOR DESIGN FROM 
NATURAL PRODUCTS 
6.1. ACE Inhibitors that Bind to the Non-Prime Binding Site 
The naturally occurring phosphonotripeptide K-26 was initially 
discovered by fractionation of extracts of a soil dwelling 
prokaryote, “actinomycete strain K-26”. Although its target among 
soil bacterium is unknown, K-26 is a potent ACE inhibitor 
(comparable to captopril) containing an unusual -amino 
phosphonic acid analogue of tyrosine [91,92]. Recently, it has also 
been determined that phosphonyl substitution is a critical 
determinant of activity, resulting in a 1500-fold increase in ACE 
inhibition when compared to its carboxyl analogues [93]. In 
addition, the absolute configuration of the terminal -amino 
phosphonate and N-acetylation were found to be important for 
modulation of ACE inhibitory activity. Recently, a structural basis 
of K-26 binding was provided through a detailed 3D structure of 
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Fig. (5). Chemical structures of ACE/ECE-1 dual inhibitors FI and FII and their potency. Compound FI adopts S configuration and compound FII adopts R
configuration [90]. 
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AnCE (a homologue of ACE from Drosophila melanogaster with a 
single enzymatic domain) with K-26 at 1.96 Å resolution [94]. The 
structure revealed that the inhibitor K-26 only occupies the S2 and 
S1 pockets (i.e., non-prime pockets of the active site). Based on this 
complex it was possible to predict how K-26 might interact with the 
N- and C-domain active sites in human somatic ACE. Thus the new 
structure provides useful information for further exploration of 
ACE inhibitor pharmacophores involving phosphonic acids and 
other K-26 related natural products and analogues.  
6.2. Vitamin B12 Derivatives as Possible ACE Inhibitors 
While captopril is not used as widely as other ACE inhibitors 
due to its side effect profile, sulfhydryl containing ACE inhibitors 
are advantageous in terms of their ability to stimulate nitric oxide 
activity and reduce oxidative stress in hypertensive patients. 
Mukherjee et al. [95] recently reported that the synthesis of 
captopril-cobalamin (a derivative of vitamin B12 in which captopril 
is bound via its thiol group at the -axial site of cobalamin) could 
improve captopril in terms of absorption, cellular uptake and tissue 
penetration. Moreover, it is likely that the compound would have 
less adverse reactions arising from its sulfydryl group. Structural 
characterisation of this molecule by X-ray diffraction and nuclear 
magnetic resonance (NMR) spectroscopy showed the formation of 
two isomers of the inhibitor which differ in the stereochemistry of 
captopril – the trans isomer is formed preferentially in the solid 
state. This study provides an additional avenue for the exploration 
of non-conventional vitamin B12 derivative/s as potential ACE 
inhibitor/s. 
7. CONCLUSIONS 
ACE inhibitors have long been established as a frontline 
therapy in the treatment of hypertension and look set to remain a 
standard treatment for this disease in the forseeable future. Recent 
advances have led to the development of domain-selective ACE 
inhibitors, which may provide new therapeutic avenues for ACE 
inhibition. These include C-domain selective inhibitors, which may 
offer improved side-effect profiles as compared with conventional 
ACE inhibitors, as well as N-domain selective inhibitors, which 
may prove useful in the treatment and prevention of fibrosis.  
The development of dual inhibitors is an approach to inhibitor 
design that has gained a lot of attraction in the drug discovery 
industry. While clinical studies showed ACE/NEP dual inhibitors 
were more efficacious than single ACE inhibitor treatment, the 
increase occurence of adverse effects have halted the progression of 
lead compounds to the market. However an ACE/ECE-1 dual 
inhibitor (selective for the C-domain of ACE) has shown promising 
results in short-term SHR experiments. In addition, treatment with 
both ACE and chymase inhibitors showed improved efficacy 
compared to ACE inhibitor monotherapy in an animal model, 
indicating that there is potential for an ACE-chymase dual inhibitor. 
Thus, dual ACE inhibitors may well usher in a new line of 
hypertensive treatments, further extending the scope of ACE 
inhibiting drugs used in the treatment of cardiovascular and other 
disease. Undoubtedly, the use of the 3D structures of these enzymes 
will be a vital aid in the successful design of such dual ACE 
inhibitors.  
Fig. (6). Details of FII binding in C- and N-domain ACE active sites [57]. A) Interaction for C-domain with the dual inhibitor at the primary site FII (site I). 
B). Interaction for N-domain with the dual inhibitor at the primary site FII (site I). C). Interaction of C-domain with dual inhibitor at the secondary binding site 
FII (site II) and D) Comparison of residues at the N-domain active site which precludes the binding of FII at site II. 
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 The development of easily crystallisable forms of both ACE 
domains has opened the way for more high throughput analysis of 
enzyme-inhibitor complexes, which will hopefully allow for 
increased development of rationally designed ACE inhibitors, 
particularly with respect to domain selective and dual ACE 
inhibitors.  
Additionally, the identification of ACE inhibiting compounds in 
natural products may help develop novel lead compounds and shed 
light on the evolution of natural product biosynthetic gene clusters.
The analysis of natural product libraries may be particularly 
insightful when combined with a structure-based screening process, 
potentially helping to identify a range of novel ACE inhibitors. 
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ABBREVIATIONS 
ACE = Angiotensin-I converting enzyme 
tACE = testis angiotensin-I converting enzyme 
sACE = somatic angiotensin-I converting enzyme 
Ang 1-7 = angiotensin (1-7) 
 (A-beta42) = amyloid beta peptide 
CHO = chinese hamster ovary 
ECE-1 = endothelin converting enzyme-1 
GnRH = gonadotropin-releasing hormone (GnRH) 
LHRH = luteinizing-hormone-releasing hormone 
NB-DNJ = N-butyldeoxynojirimycin 
NEP = neprilysin 
NMR = nuclear magnetic resonance 
CVD = cardiovascular disease 
RAAS = renin-angiotensin aldosterone system 
AcSDKP = N-acetyl-seryl-aspartyl-lysyl-proline 
RXPA380 = (Cbz-Phe[P(O)(OH)CH]Pro-Trp-OH) 
RXP407 = (Ac-Asp-(L)Phe(PO2CH2)(L)Ala-Ala-NH2)
RMSD = root mean square deviation 
SHR = spontaneous hypertensive rat 
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